Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2.
Where this comes from
- Record sourced from PubMed, PMID 34468703.
- Also identified by DOI 10.1001/jamaneurol.2021.3287 and PMC identifier 8411356.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study establishes rates of Guillain-Barré syndrome relapse among Pfizer-BioNTech BNT162b2 vaccine receivers.
Medical subject headings
- COVID-19 Vaccines
- Guillain-Barre Syndrome